Reduction of cell-cell communication in prostate cancer using STEAP-1 siRNA

US7939503B2 · kind B2 · utility

Assignee

• Latency, LLC · US

Inventors

• Aya Jakobovits · Beverly Hills, US
• Soudabeh Etessami · Calabasas, US
• Pia M. Challita-Eid · Calabasas, US
• Juan J. Perez-Villar · Mercerville, US
• Karen Jane Meyrick Morrison · Santa Monica, US
• Xiao-Chi Jia · Los Angeles, US
• Mary Faris · Los Angeles, US
• Jean Gudas · Los Angeles, US
• Arthur B. Raitano · Los Angeles, US

Key dates

• Filing date: Jun 4, 2004
• Grant date: May 10, 2011
• Expiry date: Aug 7, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.